Szeged researchers propose framework to flag antibiotic resistance risks earlier

Researchers in Szeged say a new five-step framework could help drug developers spot antibiotic resistance risks before clinical trials. The approach is meant to improve candidate selection, guide redesigns and reduce late-stage failures.

Why it matters: - Antibiotic candidates can look strong in the lab and still fail in clinical trials once bacteria evolve resistance. - Early risk screening could help researchers prioritize better compounds, redesign vulnerable molecules and avoid expensive late-stage failures. - The framework also addresses a second risk: some resistance mechanisms may make pathogens harder to treat and potentially more harmful to patients.

What happened: - Researchers from the HUN-REN Biological Research Centre, Szeged, and the Hungarian Centre of Excellence for Molecular Medicine in Szeged outlined a five-step decision-making framework in Nature Reviews Microbiology. - The authors are Csaba Pál, Petra Szili and Szilvia Juhász. - The framework is designed to identify resistance risks early in antibiotic development and group candidates into five main risk categories.

The details: - The framework looks beyond whether resistance can emerge. - It also examines whether resistance persists without antibiotics. - It checks whether resistance makes pathogens more dangerous. - It assesses whether resistance reduces the effectiveness of other drugs. - It considers whether resistance genes could spread to other bacteria. - The goal is to help developers decide which compounds to prioritize, redesign or narrow to more targeted uses. - The approach is not only about rejecting risky candidates. - Genetic changes that allow bacteria to evade a drug could also inform redesign of the molecule itself. - The authors say laboratory evolution experiments, genetic analyses and methods for identifying resistance genes already exist and can support the framework. - A 2025 study in Nature Microbiology examined 13 recently approved or in-development antibiotics and found possible resistance routes for almost all of them, with major differences across bacterial species. - That finding suggests results from one bacterial strain cannot predict an antibiotic's future across all pathogens. - The article cites GSK2251052 as an example of a promising compound that later ran into resistance during phase II trials, leading to discontinuation for complicated urinary tract and systemic Gram-negative infections in 2012. - The compound has since been studied again against non-tuberculous mycobacteria.

Between the lines: - The framework reflects a shift from treating resistance as a late-stage surprise to treating it as a development variable. - That matters because resistance can change not just whether a drug works, but how and where it should be used. - The review also highlights that resistance can alter bacterial surface features in ways that affect immune interactions. - Szilvia Juhász said researchers need to study not only whether bacteria survive an antibiotic, but also how resistance may change their ability to damage host tissues. - Csaba Pál said early warnings about evolutionary weak points could save time and resources and improve the odds of developing durable treatments.

What's next: - The Szeged team wants resistance prediction to become a routine step in antibiotic development, alongside efficacy and safety testing. - The authors expect future antibiotic design to account for how bacteria may evolve after exposure, not just how well a compound works at the start. - The framework could help guide which compounds move forward, which are redesigned and which are reserved for more targeted clinical use.

The bottom line: - The proposed framework aims to make antibiotic development more evolutionary aware, so promising drugs fail less often and last longer once they reach patients.